Clinical Trials Browser

Interventional × Uveal Melanoma × Melphalan × Clear all

NCT04812470 2025-09-22

HAITILS

Phase 1 Completed

Uveal Melanoma, Melanoma

NCT07183852 2025-09-19

GoTIL-01

Phase 1 Not yet recruiting

Uveal Melanoma, Melanoma

NCT05893654 2025-09-15

MELCOM

Phase 1/2 Enrolling by invitation

Uveal Melanoma, Melanoma

NCT02678572 2023-12-21

FOCUS

Phase 3 Completed

102 enrolled 1 FDA

Uveal Melanoma

NCT05022901 2023-12-21

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Phase 3 Active not recruiting

Uveal Melanoma

NCT05903937 2023-06-15

HAITILS-PHP

Phase 1 Not yet recruiting

Uveal Melanoma, Melanoma

NCT00324727 2021-06-21

Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma

Phase 3 Completed

Uveal Melanoma, Melanoma, Neoplasm Metastasis

NCT00096083 2013-10-23

Hepatic Arterial Infusion of Melphalan With Hepatic Perfusion in Treating Patients With Unresectable Liver Cancer

Phase 2 Completed

DermatologicEndocrineGastrointestinal

Adenocarcinoma Of Esophagus, Uveal Melanoma, Appendiceal Neoplasms, Bile Duct Neoplasms, Colonic Neoplasms, Vipoma, Esophageal Neoplasms, Gallbladder Neoplasms, Glucagonoma, Carcinoma, Hepatocellular, Insulinoma, Melanoma, Neoplasms, Pancreatic Neoplasms, Pheochromocytoma, Rectal Neoplasms, Somatostatinoma, Stomach Neoplasms, Carcinoma, Islet Cell, Carcinoma, Medullary